Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2008

View Archived Issues

Responses seen with WT1 peptide vaccine in glioblastoma multiforme patients

Amitiza hits U.S. market following recent presentations of phase III clinical trials

Migenix refocuses its programs

Age-related NADH oxidase as a potential target for skin aging therapy

COMT inhibition as a potential therapeutic strategy for schizophrenia

Phase III results reveal efficacy of ospemifene for vulvovaginal atrophy symptoms

ABT-089 improves the symptoms of attention deficit hyperactivity disorder in adults

BiPar Sciences commences phase II BSI-201 study in uterine carcinosarcoma

Juvaris initiates phase I JVRS-100 adjuvanted seasonal influenza vaccine trial

Provectus initiates phase II PH-10 trial in atopic dermatitis

Santaris begins human clinical testing of HCV drug candidate SPC-3649

Sonus and OncoGenex Technologies merge

NicOx completes enrollment in phase III clinical trial of naproxcinod in osteoarthritis

Isis to receive USD 4.6 million from Alnylam resulting from transaction with Takeda

New treatments for dental diseases reported in recent University of Tokyo patent

Recent Chugai patent describes novel antibody for hemophilia

Pluristem reports results from animal trials of PLX cells for IBD

FDA accepts for filing Watson's NDA for oxybutynin chloride topical gel for overactive bladder

Novel analgesic agents imparted in recent patent literature

Ablynx initiates phase Ib study of antithrombotic ALX-0081 for von Willebrand factor

NeuroSearch issues new shares to finance milestone payment related to ACR-16

NanoViricides enters nondisclosure agreements for nanoviricide drug candidate in EKC

Roche completes acquisition of Piramed

Rolling NDA commences for Lucassin in hepatorenal syndrome type 1

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...